Abstract
With the recently completed sequencing and annotation of the human genome, it has become clear that a significant portion of the genome encodes signal-transducing molecules including receptors, protein kinases, ion channels, transporters and coupling proteins. This review focuses on membrane-localized receptors, which represent the largest single group of signal-transducing molecules. Indeed, one can estimate that nearly 10% of the human genome encodes membrane- localized receptors (e.g. G-protein coupled receptors, ligand-gated ion channels and transporters). We have defined that portion of the human genome that encodes receptors the receptorome. In this article, we will demonstrate how the massively parallel screening of the receptorome provides a facile and under-utilized screening platform for drug discovery. Using case studies, we will show how receptorome-based screening elucidates the mechanisms responsible for serious side-effects of both approved and investigational medications. Additionally, we will provide evidence that receptorome- based screening provides insights into novel therapeutic indications of approved medications and serves to validate targets for therapeutic drug discovery.
Keywords: Obesity-Related Molecular Targets, In Silico Receptoromics, Receptor Databases, GPCR, NC-IUPHAR, Weight Gain
Current Pharmaceutical Design
Title: Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Volume: 12 Issue: 14
Author(s): Wesley K. Kroeze and Bryan L. Roth
Affiliation:
Keywords: Obesity-Related Molecular Targets, In Silico Receptoromics, Receptor Databases, GPCR, NC-IUPHAR, Weight Gain
Abstract: With the recently completed sequencing and annotation of the human genome, it has become clear that a significant portion of the genome encodes signal-transducing molecules including receptors, protein kinases, ion channels, transporters and coupling proteins. This review focuses on membrane-localized receptors, which represent the largest single group of signal-transducing molecules. Indeed, one can estimate that nearly 10% of the human genome encodes membrane- localized receptors (e.g. G-protein coupled receptors, ligand-gated ion channels and transporters). We have defined that portion of the human genome that encodes receptors the receptorome. In this article, we will demonstrate how the massively parallel screening of the receptorome provides a facile and under-utilized screening platform for drug discovery. Using case studies, we will show how receptorome-based screening elucidates the mechanisms responsible for serious side-effects of both approved and investigational medications. Additionally, we will provide evidence that receptorome- based screening provides insights into novel therapeutic indications of approved medications and serves to validate targets for therapeutic drug discovery.
Export Options
About this article
Cite this article as:
Kroeze K. Wesley and Roth L. Bryan, Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery, Current Pharmaceutical Design 2006; 12 (14) . https://dx.doi.org/10.2174/138161206776873680
DOI https://dx.doi.org/10.2174/138161206776873680 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 2
Current Cardiology Reviews Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Different Lifestyles in Young Women From Urban and Rural Areas May Explain Different Cardiovascular Risk
Vascular Disease Prevention (Discontinued) Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Influence of Ultrasound Mediated Transdermal Delivery of Losartan Potassium
Drug Delivery Letters Review of Rational Approaches to the Treatment of Pain Management-Role forOpioids Therapies
Current Drug Therapy Heart Rate Variability Analysis at Coronary Artery Disease and Angina Pectoris
Recent Patents on Cardiovascular Drug Discovery Exploring QSAR of Flavonoids as Scavengers of Peroxynitrite Using Electrotopological State (E-State) Atom Parameter
Letters in Drug Design & Discovery A New Perspective of Cannabinoid 1 Receptor Antagonists: Approaches Toward Peripheral CB1R Blockers without Crossing the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets Benefits of Olive Oil Phenolic Compounds in Disease Prevention
Endocrine, Metabolic & Immune Disorders - Drug Targets Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Current Topics in Medicinal Chemistry An Update to Enterococcal Bacteremia: Epidemiology, Resistance, and Outcome
Infectious Disorders - Drug Targets The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Menopause, A Universal Female Experience: Lessons from Mexico and Central America
Current Women`s Health Reviews Streptokinase: An Efficient Enzyme in Cardiac Medicine
Protein & Peptide Letters Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design